Few corners of the peptide conversation are as tangled as growth hormone. Ipamorelin, CJC-1295, tesamorelin, sermorelin, GHRPs — the names get used almost interchangeably, as if they were flavors of the same thing. They are not. They act on the growth hormone system through different doors, and understanding those doors is the key to understanding why these compounds are not simply substitutes for one another.

The growth hormone axis, briefly

Growth hormone (GH) is released by the pituitary gland, but it is not released steadily. It comes out in pulses — bursts throughout the day and especially during deep sleep — and that pulsatile rhythm is biologically important. The body regulates these pulses with two opposing signals from the hypothalamus: growth-hormone-releasing hormone (GHRH), which tells the pituitary to release GH, and somatostatin, which tells it to stop. Layered on top is a third input: ghrelin, the so-called “hunger hormone,” which also potently stimulates GH release through its own dedicated receptor.

That gives us two distinct molecular targets for raising GH — the GHRH receptor and the ghrelin receptor (technically GHS-R1a) — and this is the fork that separates the compounds.

Two families, two mechanisms

GHRH analogs are synthetic versions of the body’s own “release” signal. They bind the GHRH receptor and encourage the pituitary to secrete GH in its natural, pulsatile pattern. Tesamorelin and sermorelin are examples. Tesamorelin is the evidence standout here for one reason worth emphasizing: it is FDA-approved and backed by large randomized human trials (for reducing visceral fat in HIV-associated lipodystrophy), which makes it the most evidence-rich molecule in this entire category and a useful benchmark for what real clinical data looks like.

Ghrelin-receptor agonists — also called growth-hormone secretagogues (GHS) — work through the other receptor entirely. This family includes the GHRPs and ipamorelin. They mimic ghrelin at the GHS-R1a receptor to trigger GH release. Ipamorelin was designed for selectivity: unlike some earlier secretagogues, it was developed to stimulate GH with minimal effect on cortisol and prolactin in preclinical models, which is much of the reason it drew interest.

Because the two families act through different receptors, they are not redundant, and researchers have long been interested in how GHRH-pathway and ghrelin-pathway stimulation interact. Experimental work has shown that combined signaling can produce greater GH release than either pathway alone, although the magnitude and pattern depend on the specific molecules and conditions studied.

Where CJC-1295 fits — and the DAC distinction

CJC-1295 is a GHRH analog best known for a formulation feature worth understanding, because it is a frequent source of confusion. The “DAC” in CJC-1295 with DAC stands for Drug Affinity Complex — a modification that lets the molecule bind to albumin in the blood, dramatically extending its half-life. In healthy adults, a single dose of CJC-1295 with DAC produced prolonged elevation of growth hormone and IGF-1, with an estimated half-life on the order of a week. Intriguingly, that same human study found that the body’s pulsatile pattern of GH secretion persisted despite the sustained exposure — so the biology is more nuanced than describing DAC as simply flattening the pulse into a continuous signal.

A naming caution matters here. In commercial peptide discussions, “CJC-1295 without DAC” is often used as shorthand for a shorter-acting modified GHRH analog commonly called Mod GRF 1-29 — which is not simply the long-acting molecule with the DAC removed. That terminology can blur real molecular differences, so the exact compound being discussed matters more than the label alone.

Why “same axis” does not mean “interchangeable”

Here is the throughline. All of these compounds raise growth hormone, but how they do it — which receptor, in what pattern, over what duration, with what selectivity, and with how much human evidence behind them — varies enormously. Tesamorelin sits on a foundation of randomized trials and an approval; ipamorelin and CJC-1295 rest on a much earlier-stage research base, with far less controlled human data. A GHRH analog and a ghrelin-receptor agonist engage different biology. A DAC-modified peptide and an unmodified one produce different signaling profiles.

Treating them as one interchangeable group flattens all of that — and the differences are the interesting part. The growth hormone axis is a beautifully regulated system, and the molecules that act on it are a case study in how much the mechanism of an intervention shapes what it actually does.

Where this goes

This piece is meant as a map. Each of these compounds — ipamorelin, CJC-1295, tesamorelin, and the broader question of GH pulsatility itself — rewards a closer look, and we will give several of them their own articles. But the foundation is this: when you see these names grouped together, remember that they are not variations on a theme so much as different answers to the same question, and the science lives in how those answers differ.